Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

DOHMEN NEWS

Learn what's happening in the world of Dohmen and our clients
August 23, 2013

Dohmen Donates Building to Assist Homeless

Milwaukee-based Dohmen chief executive officer Cynthia LaConte announced today donation of a building that had previously served as the West Bend headquarters for its Restat division.
learn more
August 19, 2013

Dohmen Sells Restat for $409.5 Million

Lisle, Ill.-based Catamaran Corp. plans to buy Milwaukee-based Restat from its parent company, Milwaukee-based Dohmen, for $409.5 million, in a deal slated to close in the fourth quarter of this year. Catamaran is a pharmacy benefit management firm. Restat is a benefits management firm, and Dohmen is a life science services company.
learn more
August 01, 2013

Dohmen Co. Sells Restat Business for $409.5 Million

Dohmen Co. of Milwaukee said it sold its Restat business for $409.5 million to pharmacy benefit manager Catamaran Corp.
learn more
August 01, 2013

Dohmen to Sell Restat Unit to Catamaran Corp. for $409.5 Million

Dohmen, a Milwaukee company that provides an array of technical services to life sciences companies, has agreed to sell Restat, which manages prescription drug benefits, for $409.5 million. The sale to Catamaran Corp., a pharmacy benefit manager based in Lisle, Ill., is expected to close in the fourth quarter of this year.
learn more
December 27, 2012

In an EHR Era, Adverse Event Reporting Takes on a New Look

In Oct. 2012, the Health IT Policy Committee, which advises the Office of the National Coordinator for Health IT, released preliminary recommendations for Stage 3 meaningful use requirements for electronic health records (EHRs). Included in those recommendations are a requirement that certified EHRs (those that are eligible for federal incentive payments) be capable of reporting adverse drug events to FDA and/or the Centers for Disease Control and Prevention.
learn more
October 03, 2012

Patients, Companies and Professionals Converge to Plan for a Better Future for Rare Diseases

Centric Health Resources opened its doors to attendees of its 5th annual Ultra-Orphan Drug Conference in St. Louis, Missouri. Nestled in the heartland of the USA, the Centric team instantly made attendees feel like part of the family. This year’s conference again spotlighted both orphan and ultra-orphans diseases, their needs, and their strengths. Although there is no legal definition to differentiate between an orphan disease and an ultra-orphan disease, many concur that there thousands of rare diseases that occur so rarely that they warrant the tag of being categorized as ultra-orphan. Despite the low numbers, that has not deterred companies from pursing treatments for ultra-orphan diseases and orphan diseases alike.
learn more
October 01, 2012

On Wisconsin! How the Badger State is Writing Its Next Chapter as a Biotech Innovator and Entrepreneur Magnet

If your knowledge of Wisconsin is limited to the state's iconic sports franchises, its cheese and beer and news reports about union rights or Mitt Romney's running mate, you really haven't been paying attention. Wisconsin's leaders tell a story of a state that's reinvented itself, that attracts cutting-edge biotechnology companies and has a vital entrepreneurial culture and a major global niche in water technology.
learn more
July 31, 2012

A Conversation With Cynthia LaConte, Dohmen Company

Dohmen grew historically by building greenfield operations in response to client needs. Both RESTAT and DDN are successful examples of that approach. Yet, while having an in-house development team to bring new capability to market remains an important part of our growth strategy, it takes awhile. We wanted to accelerate development timelines in key strategic areas, so we added acquisition to the mix.
learn more